Popular weight loss drugs tied to unexpected nail condition

KUALA LUMPUR, 13 OCTOBER 2026 —

Popular GLP‑1 weight‑loss drugs have been linked to a markedly higher incidence of nail detachment, hair loss and scalp inflammation, a multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 showed.

The study examined 575 adults who were currently using a GLP‑1 medication and compared them with 1,329 control participants who had type‑2 diabetes and/or obesity but had never taken a GLP‑1 drug. Participants were recruited from France, the United States, Brazil and Mexico. Overall, 66 % of GLP‑1 users reported at least one nail disorder, versus 53 % of the control group.

Nail detachment—a condition in which the nail separates from the underlying skin—was reported by 39 % of users, more than four times the 9 % reported by non‑users. Nail discoloration affected 46 % of users compared with 17 % of controls.

Researchers explored whether rapid weight loss, a known trigger of nail and hair changes, could explain the disparity. Even after restricting the analysis to participants who had lost weight, GLP‑1 users continued to report significantly more nail problems than non‑users. “Until now, nail changes associated with GLP‑1 therapies had essentially been anecdotal,” said study author Dr Charles Taïeb.

“Our findings show a clear association, but they also underline an important point: not everything that happens during GLP‑1 treatment is necessarily caused by the treatment itself.”

The association persisted after adjusting for pre‑existing skin conditions and nutritional deficiencies, although the magnitude of the differences narrowed. Nail detachment and discoloration remained roughly two to three times more common among GLP‑1 users than among controls after these adjustments. Approximately half of the medication users reported that nail problems had begun before they started GLP‑1 therapy, underscoring that the drugs are not the sole driver of the observed symptoms.

A companion analysis of the same cohort revealed parallel abnormalities in hair and scalp health. Half of GLP‑1 users reported unusual hair loss, compared with 34 % of non‑users. Reduced hair volume or density was reported by 42 % of users versus 19 % of controls. Hair loss that began after treatment initiation was noted by 26 % of users, more than double the 12 % reported by non‑users.

Scalp redness—a sign of inflammation—was approximately three times more frequent among GLP‑1 users.

Most participants who experienced hair shedding also reported additional scalp symptoms such as itching, redness or flaking skin. “This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component,” explained study author Dr Bruno Halioua. “Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable.”

The researchers cautioned that the studies were cross‑sectional, relying on self‑reported symptoms rather than standardized clinical examinations, and therefore could not establish causality. “These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative,” said Dr Halioua. “Anyone who notices hair shedding, an itchy or red scalp or nail changes should mention it to their doctor rather than discontinue therapy.”

To move beyond association, the team plans prospective investigations that will follow patients from the start of GLP‑1 therapy, incorporate standardized dermatological assessments and include biological monitoring. The aim is to pinpoint when nail, hair and scalp changes first appear, elucidate underlying mechanisms and determine whether the alterations resolve over time or require specific interventions.

The research received institutional support from DUCRAY Laboratories, a subsidiary of the Pierre Fabre Group that develops dermatological and hair‑care products. Materials for the study were provided by Beyond.

The presentation of these data at a major dermatology congress signals a shift toward broader surveillance of GLP‑1 therapy side‑effects, an issue that may influence prescribing practices across Malaysia and the wider region where obesity and diabetes prevalence are rising and GLP‑1 agents are being adopted rapidly.